Topical compositions and methods for using topical compositions comprising tapinarof to treat chronic mild to moderate plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.
